Intracranial Arteriosclerosis (Cerebral Atherosclerosis)

Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.
Also Known As:
Cerebral Atherosclerosis; Cerebral Arteriosclerosis; Intracranial Atherosclerosis; Arterioscleroses, Cerebral; Arterioscleroses, Intracranial; Arteriosclerosis, Cerebral; Arteriosclerosis, Intracranial; Atheroscleroses, Cerebral; Atheroscleroses, Intracranial; Atherosclerosis, Cerebral; Atherosclerosis, Intracranial; Cerebral Arterioscleroses; Cerebral Atheroscleroses; Intracranial Arterioscleroses; Intracranial Atheroscleroses
Networked: 309 relevant articles (11 outcomes, 34 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Stroke (Strokes)
2. Intermittent Claudication
3. Pathologic Constriction (Stenosis)
4. Hypertension (High Blood Pressure)
5. Diabetes Mellitus


1. Meyers, Philip M: 9 articles (12/2010 - 01/2004)
2. Higashida, Randall T: 8 articles (12/2010 - 01/2004)
3. Sacks, David: 6 articles (12/2010 - 10/2005)
4. Hopkins, L Nelson: 6 articles (11/2010 - 04/2004)
5. Levy, Elad I: 6 articles (11/2010 - 04/2004)
6. Liebeskind, David S: 5 articles (05/2015 - 01/2012)
7. Kim, Jong S: 5 articles (03/2015 - 05/2011)
8. Wojak, Joan C: 5 articles (01/2014 - 10/2005)
9. Lavine, Sean D: 5 articles (12/2010 - 01/2005)
10. Schumacher, H Christian: 5 articles (12/2010 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Intracranial Arteriosclerosis:
1. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
2. cilostazol (Pletal)FDA LinkGeneric
3. EndostatinsIBA
01/01/2005 - "A predominance of the inhibitor endostatin within the endogenous angiogenic response is associated with a greater extent and risk of recurrence of symptomatic intracranial atherosclerosis, suggesting that angiogenesis may be beneficial in this condition."
01/01/2005 - "Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence."
01/01/2005 - "We aimed to investigate the relationship between the pro-angiogenic vascular endothelial growth factor (VEGF) and the anti-angiogenic endostatin, and the extent and risk of recurrence of symptomatic intracranial atherosclerosis. "
01/01/2005 - "Diabetes mellitus (OR, 6.04; CI, 1.1 to 32.2; P=0.03) and a higher endostatin/VEGF ratio (OR, 15.7; CI, 2.2 to 112.3; P=0.006) were independently associated with a greater extent of intracranial atherosclerosis. "
01/01/2005 - "Studies performed by our group in patients with symptomatic intracranial large-artery atherosclerosis have shown that: (1) C-reactive protein predicts its progression and recurrence, suggesting that inflammation may play a deleterious role in this condition; (2) a high level of the anti-angiogenic endostatin is also associated with a progressive and recurrent intracranial atherosclerosis, which might support a beneficial role for angiogenesis in this group of patients; and (3) elevated lipoprotein(a) concentration and diabetes mellitus characterize those patients with a higher number of intracranial stenoses."
4. CalciumIBA
5. TaurineFDA Link
6. PapaverineIBA
7. 10-N-nonylacridinium orange (NAO)IBA
8. diazonaphthalenedisulfonic acid (NDS)IBA
9. Warfarin (Coumadin)FDA LinkGeneric
10. glucuronyl glucosamine glycan sulfate (Vessel)IBA

Therapies and Procedures

1. Catheters
2. Angioplasty (Angioplasty, Transluminal)
3. Stents
4. Chinese Traditional Medicine (Traditional Chinese Medicine)
5. Baths